Onconetix Management

Management criteria checks 0/4

Onconetix's CEO is Ralph Schiess, appointed in Dec 2023, has a tenure of less than a year. directly owns 5.97% of the company’s shares, worth €1.33M. The average tenure of the management team and the board of directors is 1.8 years and 1.8 years respectively.

Key information

Ralph Schiess

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	6.0%
Management average tenure	1.8yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO

Ralph Schiess (45 yo)

less than a year

Tenure

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ralph Schiess	Interim CEO & Chief Science Officer	less than a year	no data	5.97% € 1.3m
Karina Fedasz	Interim Chief Financial Officer	less than a year	no data	no data
Brian Price	Head of Technology Strategy	4.2yrs	US$126.48k	no data
Frank Jaeger	Senior VP of Marketing & Business Development	1.8yrs	no data	no data
Andrew Skibo	Global Head of Biologics Operations	3.4yrs	no data	no data
Theodore Yoho	Head of Business Development	3.4yrs	no data	no data
Ali Fattom	Head of Science & Discovery	2.2yrs	no data	no data
Jay Newmark	Chief Medical Officer	1.6yrs	no data	no data
Christian Bruhlmann	Chief Strategy Officer & GM of Europe	less than a year	no data	5.23% € 1.2m
Donald Very	Senior VP of Commercial Research & Development	no data	no data	no data

1.8yrs

Average Tenure

49yo

Average Age

Experienced Management: J4T0's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
John Rice	Member of Scientific Advisory Board	no data	no data	no data
Thomas Meier	Director	less than a year	no data	0.040% € 8.9k
James Sapirstein	Non Executive Chairman & Lead Independent Director	2.8yrs	US$182.12k	0.042% € 9.3k
Ajit Singh	Independent Director	less than a year	no data	0.041% € 9.1k
Sunetra Gupta	Member of Scientific Advisory Board	no data	no data	no data
Simon Tarsh	Independent Director	2.3yrs	US$112.62k	0.042% € 9.3k
Timothy Ramdeen	Independent Non-Executive Director	1.8yrs	US$82.67k	0.042% € 9.3k

1.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: J4T0's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Onconetix Management

Management criteria checks 0/4

Key information

Recent management updates

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Recent updates

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(a)(1)

Onconetix, Inc. announced that it expects to receive $27 million in funding

Onconetix Provides Non-Compliance Update

Onconetix, Inc. announced that it expects to receive $5 million in funding

Onconetix, Inc. announced delayed 10-Q filing

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

New major risk - Financial position

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

High number of new and inexperienced directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

CEO, President & Executive Chairman recently sold €2.7m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age